-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer, the most commonly diagnosed cancer, is one of the leading causes of cancer-related death worldwide.
lung cancer is classified in histology as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which accounts for about 85% of the total cases.
lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the two most common subsypes of NSCLC.
an important form of cancer gene addiction in cancer cells that circumvent the process of cellular programmed death: cancer cells are subjected to enormous cellular pressure during transformation and unstomic proliferation and rely on signaling path paths to maintain their survival.
understanding the molecular mechanisms that sustain cancer cell survival can provide the basis for potential interventional therapy.
of MRL-1 in lung cancer is intended to explore the role of survival-promoting genes in cancer cell integrity during the cloning evolution of non-small cell lung cancer (NSCLC).
researchers found high-frequency MCL-1 obtained expression in several separate NSCLC queues, both in tumor cloning and subclonals.
lack of functional TP53 is significantly related to the subclonal expression of MCL-1.
in mouse models, pharmacological or genetic inhibition of THEL-1 expression can delay tumor development.
in general, the above results show that high-frequency MCL-1 obtained expression in pulmonary adenocarcinoma may be a potential therapeutic target for the disease.
.
